Alexo Therapeutics marks next significant milestone by initiating ALX148 combination cohorts - News-Medical.net

News-Medical.net
Alexo Therapeutics marks next significant milestone by initiating ALX148 combination cohorts
News-Medical.net
Alexo Therapeutics, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced it has initiated ALX148 combination dosing with targeted antibody therapies in its Phase 1 clinical program in ...